Key Takeaways
- Shares of BSX plummeted 9% to $62.93, marking the lowest closing price since January 2024
- CHAMPION-AF trial demonstrated Watchman FLX was non-inferior to anticoagulants, though ischemic stroke incidence reached 3.2% versus 2% for blood thinners
- Raymond James lowered BSX from Strong Buy to Outperform and reduced its price target from $97 to $88
- Analysts pointed to decelerating momentum in U.S. electrophysiology and Watchman divisions, representing over half of the company’s annual growth
- Year-to-date, BSX has declined 34%, significantly underperforming the S&P 500’s 7.1% drop
Boston Scientific experienced a challenging trading session on Monday, with shares plummeting 9% following a combination of clinical trial data that disappointed investors and a Wall Street downgrade.
Boston Scientific Corporation, BSX
Presented on March 30 at a medical conference, the CHAMPION-AF trial evaluated the Watchman FLX left atrial appendage closure device. The study demonstrated that the device met its non-inferiority endpoint when compared to contemporary anticoagulants including Eliquis and Xarelto. Additionally, patients receiving the Watchman device experienced lower rates of non-procedural bleeding, achieving the trial’s primary goal.
However, market participants focused on a concerning detail within the data. The ischemic stroke incidence among Watchman patients reached 3.2%, compared to just 2% in the anticoagulant group. This disparity, despite being relatively modest, triggered significant investor anxiety.
It’s important to recognize that this difference lacked statistical significance and wasn’t designated as a primary study outcome. Investigators intend to monitor participants for five years to obtain more comprehensive long-term stroke risk data.
Medical Experts Defend Trial Outcomes
Study co-chair Marty Leon characterized the findings as “a very strong endorsement” supporting broader device utilization. He presented the risk-benefit calculation transparently: a 0.33% annualized elevation in stroke or embolization risk balanced against approximately 2.6% reduction in bleeding complications. Boston Scientific’s chief medical officer Ken Stein reinforced this perspective, emphasizing that stroke rates in both cohorts remained “incredibly low.”
Truist Securities observed that overall conference sentiment was favorable. Leerink Partners indicated that firsthand reactions from attendees increased their confidence that the trial data would drive higher Watchman procedure volumes moving forward.
Despite these reassurances, the market reaction was unforgiving. BSX shares settled at $62.93, representing the weakest close since January 30, 2024.
Compounding the pressure, Raymond James issued a downgrade on the same day, moving BSX from Strong Buy to Outperform while slashing its price objective from $97 to $88. The firm highlighted diminishing growth rates in two critical revenue drivers: U.S. electrophysiology and Watchman franchises, which collectively represented 26% of 2025 sales and generated more than half of year-over-year expansion.
Raymond James Maintains Long-Term Optimism While Adjusting Forecasts
Raymond James analyst Jayson Bedford emphasized that the downgrade shouldn’t be interpreted as a fundamental concern. The firm continues to regard Boston Scientific as among the highest-quality, fastest-expanding enterprises in large-cap medical device sector. The rating adjustment reflected diminished near-term visibility rather than deteriorating long-term prospects.
The firm reduced its 2026 and 2027 revenue projections by approximately 0.5% and 1.5% respectively. Updated modeling anticipates Watchman growth of 17% and 16% across the next two years, down from previous estimates of 18% and 20%. EP growth expectations were similarly adjusted to 15% and 14%.
Notwithstanding these reductions, Raymond James contends the valuation remains compelling. BSX currently trades at roughly 18 times projected 2027 earnings, compared to a 21 times multiple for comparable companies.
Multiple other research firms — including Bernstein, Evercore ISI, Stifel, Truist, and Jefferies — maintain Buy or Outperform recommendations, with price targets spanning $88 to $120.
BSX has fallen 34% year-to-date. Shares previously reached a 52-week peak of $110 earlier this year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
